Study of Crenolanib With Ramucirumab and Paclitaxel for Advanced Esophagogastric Adenocarcinoma

Esophagogastric Adenocarcinoma Clinical Trial

Official title:
Phase I/Ib Study of Crenolanib With Ramucirumab and Paclitaxel as Second Line Therapy for Advanced Esophagogastric Adenocarcinoma

Status Completed

Clinical Trial Summary

This is a single-arm phase I/Ib study of crenolanib combined with ramucirumab/paclitaxel as second line therapy for patients with advanced/metastatic adenocarcinoma of the esophagus, GEJ or stomach. Patients will be enrolled in two phases; dose escalation phase and dose expansion phase.

Clinical Trial Description

n/a

Study Design

Related Conditions & MeSH terms

Clinical Trial Details

NCT number	NCT03193918
Study type	Interventional
Source	Arog Pharmaceuticals, Inc.
Contact
Status	Completed
Phase	Phase 1
Start date	April 14, 2017
Completion date	July 15, 2020

View Details

See also
Status	Clinical Trial	Phase
Completed	`NCT02234596` - Nintedanib in Patients With Advanced Esophagogastric Cancer	Phase 2
Active, not recruiting	`NCT05268510` - Chemotherapy and Pembrolizumab, Followed by Pembrolizumab and Olaparib as Firstline Therapy in Her-2 Negative Gastric/GEJ Adenocarcinoma	Phase 2
Recruiting	`NCT04219137` - Molecular Characteristics of Gastroesophageal Adenocarcinoma (MOCHA): A Prospective Feasibility Study
Completed	`NCT03921021` - Phase 2 Study of Telomelysin (OBP-301) in Combination With Pembrolizumab in Esophagogastric Adenocarcinoma	Phase 2
Recruiting	`NCT05504720` - Evaluating Pembrolizumab, Trastuzumab and FLOT as Perioperative Treatment of HER2-positive, Localized Esophagogastric Adenocarcinoma	Phase 2
Withdrawn	`NCT02856867` - Nintedanib Plus mFOLFOX6 for Previously Untreated Metastatic Esophagogastric Adenocarcinoma (MEGAN)	Phase 2
Recruiting	`NCT06123468` - Study Evaluating Treatment of Sacituzumab-govitecan for Patients With Metastatic Esophagogastric Adenocarcinoma	Phase 1/Phase 2